Report Library
All Reports
Breast Cancer KOL Interview – US, Midwest
July 18, 2022
A US-based key opinion leader (KOL) provides insights into prescribing habits, key marketed brands, and late-phase pipeline therapies across all three subtypes of breast cancer. Key pipeline assets highlighted include Enhertu, Trodelvy, Cosela, and enobosarm.
If you are a KOL Insight Subscriber, please access the interview from our KOL Insight portal (Subscribers only).
Biomedtracker's KOL Insight transcripts are available through subscription only. For more information on obtaining a KOL Insight subscription, please email Biomedtracker or call Biomedtracker Client Services at (888) 670-8900.
For our disclosures, please read the Biomedtracker Research Standards.| Indications Covered: | Breast Cancer |
Additional Resources:
- Breast Cancer KOL Interview – US, Northeast
- Breast Cancer KOL Interview – UK
- Datamonitor Healthcare Oncology Disease Analysis: HER2+ Breast Cancer
- Datamonitor Healthcare Oncology Disease Analysis: HR+/HER2- Breast Cancer
- Datamonitor Healthcare Oncology Disease Analysis: Triple-Negative Breast Cancer